Egetis Therapeutics AB (publ) (STO:EGTX)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.635
-0.125 (-2.63%)
Dec 5, 2025, 5:29 PM CET
-18.11%
Market Cap 1.83B
Revenue (ttm) 55.40M
Net Income (ttm) -333.30M
Shares Out 395.16M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE 19.62
Dividend n/a
Ex-Dividend Date n/a
Volume 794,801
Average Volume 2,545,671
Open 4.775
Previous Close 4.760
Day's Range 4.635 - 4.855
52-Week Range 3.025 - 7.670
Beta 1.26
RSI 40.58
Earnings Date Nov 25, 2025

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 40
Stock Exchange Nasdaq Stockholm
Ticker Symbol EGTX
Full Company Profile

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.

Financial Statements

News

There is no news available yet.